MedPath

Effect of spironolactone versus placebo in patients with a hypertensive response to exercise

Phase 3
Completed
Conditions
Pre-hypertension
Cardiovascular - Hypertension
Registration Number
ACTRN12609000835246
Lead Sponsor
niversity of Queensland
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
120
Inclusion Criteria

Hypertensive response to exercise (HRE); maximum SBP/DBP (systolic/diastolic blood pressure) response to exercise >210/105 mmHg in men and >190/105 mmHg for women

Exclusion Criteria

1) hypertension at rest (>140/90 mmHg or on treatment for hypertension), 2) known coronary artery disease (angina, previous infarction, previous positive diagnostic test), 3) diabetes mellitus

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction of fibrosis, as assessed by backscatter and strain markers[Baseline vs 3 months following randomisation]
Secondary Outcome Measures
NameTimeMethod
Improvement in diastolic function using tissue Doppler echocardiography, measured as tissue diastolic velocity (e')[Baseline and 3 months following randomisation]
© Copyright 2025. All Rights Reserved by MedPath